Corp Presentation ODYY
Total Page:16
File Type:pdf, Size:1020Kb
Developing and Acquiring Life- Saving Medical Products Investor Presentation July 2021 OTC: ODYY ©2021 Odyssey Group International | OTC: ODYY 1 Forward Looking Statements This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding Odyssey Group International, Inc.’ (“Odyssey Group International, Inc.” or the “Company”) future results of operations and financial position, including the financial results for the year ended July 31, 2020, financial targets, business strategy, plans and objectives for future operations, are forward-looking statements. The Company has based these forward-looking statements largely on its current estimates of its financial results and its current expectations and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy, short term and long-term business operations and objectives, and financial needs as of the date of this presentation. These forward- looking statements are subject to a number of risks, uncertainties and assumptions, including those described under the heading “Risk Factors” in the Company’s filings with the Securities and Exchange Commission (the “SEC”). Moreover, the Company operates in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for Company management to predict all risks, nor can the Company assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Company may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this presentation may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Moreover, neither the Company nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements. Except as required by law, the Company undertakes no obligation to update publicly any forward-looking statements for any reason after the date of this presentation, to conform these statements to actual results or to changes in the Company’s expectations. The Company’s filings with the Securities and Exchange Commission are available to you and you should read the documents the Company has filed with the SEC for more complete information about the Company. You may get these documents for free by visiting EDGAR on the SEC Web site at www.sec.gov. ©2021 Odyssey Group International | OTC: ODYY 2 About Odyssey Group International Asset acquisition company focused on unique, life-saving medical products that offer clinical advantages Strong leadership team of seasoned pharma and medical device industry veterans Multiple products in development with an array of near-term milestones Potential to commercialize products as early as 2022 ©2021 Odyssey Group International | OTC: ODYY 3 Products in Development Pharmaceuticals Medical Devices • PRV-002 CardioMap Novel compound for treatment of • Heart monitoring and screening mTBI (concussion) which currently device for early detection of has no FDA approved drug coronary artery disease • PRV-001 Save-A-Life Novel compound intended to treat • handheld choking rescue device Niemann-Pick disease; potential Orphan Drug designation ©2021 Odyssey Group International | OTC: ODYY 4 PRV-002 Novel Compound for Treatment of Concussion ©2021 Odyssey Group International | OTC: ODYY 5 About Concussion 75% Concussions, represent a significant unmet medical need Likelihood of athlete head- • > 5 Million per year in the US, 69M worldwide injury recurrence • Medical costs in the US is $10-15 Billion per year in US, $400B worldwide Current standard of care is rest, analgesics for 33% headache, anti-depressants and ADHD medications Individuals over 65 that fall annually; 50% of deaths are from brain injury Repeat concussions lead to early dementia and Chronic Traumatic Encephalopathy No currently approved FDA drug treatment exists 25x Frequency of military PTSD development post-concussion ©2021 Odyssey Group International | OTC: ODYY 6 About PRV-002 • New chemical entity: Proprietary Neurosteroid • Proven in-vivo efficacy in animal concussion models through gene amplification of anti- inflammatories, anti-oxidants and efflux fluid channels • Safety margin > 300-fold in animal toxicology studies • Nasal administration drives drug into the brain in minutes • Potential revenue worldwide over $6B with significant healthcare savings ©2021 Odyssey Group International | OTC: ODYY 7 Preclinical Results PRV-002 Significantly PRV-002 Significantly Improved Neuroscore Improved Memory Score Neurobehavioral Battery Scored sensory motor function Morris Water Maze based on 4 movement In before and after comparisons behaviors, rats subjected to of rats after subjected to concussion model and treated concussion model, rats treated with PRV-002 outperformed with PRV-002 outperformed those treated only with vehicle those treated only with vehicle ©2021 Odyssey Group International | OTC: ODYY 8 Sports Advisory Board March 2021, Odyssey announced the formation of a Sports Advisory Board The SAB will • Kurt Warner – NFL Hall of Fame, NFL MVP, Super Bowl MVP, Super support Odyssey’s Bowl Champion outreach efforts to • Brett Favre – NFL Hall of Fame Quarterback, Super Bowl Champion, 3x consecutive MVP enhance public awareness of • Abby Wambach – 2x Olympic gold medalist, World Cup champion, and winner of the FIFA World Player of the Year traumatic brain • Mark Rypien – 2x Super Bowl Champion, 1st Canadian quarterback injuries and to start in the NFL concussion as well • David Ross – Current Manager of the Chicago Cubs, 2x World as the need for an Series Champion catcher FDA approved • Steve “Mooch” Mariucci – Head coach San Francisco 49er’s from therapy. 1997-2002 and Detroit Lions from 2003-2005, current member of the NFL’s Player Safety Advisory Committee ©2021 Odyssey Group International | OTC: ODYY 9 Scientific Advisory Board James P. Kelly, MA, MD, FAAN, – Dr. Kelly is the Executive Director of the Marcus Institute for Brain Health (MIBH) and Professor of Neurology at the University of Colorado Anschutz Medical Campus in Aurora, CO. He is National Director of the Gary Sinise Foundation Avalon Network TBI Medical Programs for which the MIBH serves as the clinical coordinating center. His immediate past position was Director of the National Intrepid Center of Excellence (NICoE) at Walter Reed National Military Medical Center in Bethesda, MD. Dallas C. Hack, MD, MPH, FACMPH, COL, US Army- COL(R) Hack then served as the Command Surgeon for the US Army Central Command-Kuwait from 2001 to 2002, where he directed medical care for the US military in Kuwait, Saudi Arabia, and Qatar. He also served as Deputy Commander for Clinical Services for 3rd MEDCOM, assisting with planning medical support for Operation Enduring Freedom and providing clinical oversight over medical operations in Afghanistan and Pakistan. Dr Bob Arnot - Dr. Arnot is the former Chief Medical Correspondent at Dateline NBC, The Today Show, NBC Nightly News, CBS News, CBS Evening News, 48 Hours, and CBS This Morning. He is a New York Times best selling author. Dr. Arnot is the current Dean of Advanced Technology and International Education at the New York Film Academy. He previously served on the board for Pine Manor College and Harvard affiliated Joslin Diabetes centers Board of Incorporators and was the National Medical Director of National Emergency Services. ©2021 Odyssey Group International | OTC: ODYY 10 Timeline and Milestones PRV-002 2Q21 3Q21 4Q21 1Q22 Complete Device prototype Finalize Nanoparticle Formulation Initiate Phase 1A Trial Complete Phase 1A Trial Initiate Phase 1B Trial Complete Phase 1B Trial Meet with FDA on Phase 2 Trial ©2021 Odyssey Group International | OTC: ODYY All timing pending availability of capital resources for each program11 PRV-001 Novel compound for Treatment of Niemann-Pick type C Disease ©2021 Odyssey Group International | OTC: ODYY 12 Niemann-Pick type C Disease A rare neurodegenerative-lysosomal storage disorder • Cholesterol build-up 5-20 years • Microglia-activated Average NPC Patient Life inflammation Expectancy • Ataxia, Dysphagia and Cognitive Decline Drug Mechanism of Action 1 in 150,000 • Stimulates the Pregnane X Receptor Estimated US Prevalence • Increases export of piled-up cholesterol through the P-Glycoprotein channel 5x • Activates CD55 which reduces microglial-activated cerebellar inflammation Higher incidence in Middle Eastern populations ©2021 Odyssey Group International | OTC: ODYY 13 Orphan Drug Candidate We anticipate receiving Orphan Drug designation from the FDA for PRV-001 • NPC is considered an orphan disease by the FDA • Orphan Drug status accelerates pathway to FDA approval • Successful development of PRV-001 may earn a Pediatric Disease Priority Review Voucher If approved, Orphan Drug